Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin-Reference-Cited by-同舟云学术

Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin

Published:2020-09-28 Issue:3 Volume:61 Page:394-405
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Yee Ka Lai¹^ORCID,Cabalu Tamara D.¹,Kuo Yuhsin¹,Fillgrove Kerry L.¹,Liu Yang¹,Triantafyllou Ilias¹,McClain Sasha¹,Dreyer Daniel¹,Wenning Larissa¹,Stoch S. Aubrey¹,Iwamoto Marian¹,Sanchez Rosa I.¹,Khalilieh Sauzanne G.¹

Affiliation:

1. Merck & Co., Inc. Kenilworth New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1747

Reference26 articles.

1. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses

2. PIFELTRO™ (doravirine) prescribing information. Whitehouse Station NJ: Merck Sharp & Dohme Corp.;2019.https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf. Accessed May 14 2020.

3. 2019 DELSTRIGO™ (doravirine lamivudine and tenofovir disoproxil fumarate) prescribing information

4. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

5. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group;Clinical Pharmacology & Therapeutics;2023-12-10

2. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014;JAIDS Journal of Acquired Immune Deficiency Syndromes;2023-02-01

3. Clinical Trials and Regulatory considerations of Antiviral agents;Viral Infections and Antiviral Therapies;2023

4. Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments;Clinical Pharmacokinetics;2022-05-17

5. Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective;Clinical Pharmacology & Therapeutics;2021-12-24